FIG 7.
Therapeutic efficacy of phage MYY9 against high-mucus-yield P. aeruginosa clinical isolate FRD1 infections in chronic pneumonia mouse models. (a) Curves of bacterial loads (CFU) in infected lungs over time in the model group (PBS) and the treatment group (MYY9) when the MOI is 1. (b) Curves of bacteriophage titers (PFU) in infected lungs over time in the treatment group (MYY9). (c) Cytokine concentrations in BALF in chronic pneumonia models. (d and e) Concentration dynamics of selected inflammatory biomarkers (TNF-α and IL-6) in BALF over time. “#” indicates the time point of phage treatment, while “*” indicates a P value of <0.05. The lower limit of detection is 2 log10 units. Each group contained at least three mice. For each panel, data represent the means (±SD).